Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Humanized Anti-CD26 Monoclonal Antibody Has Anti-Myeloma Efficacy for the Treatment of High-Risk Multiple Myeloma

Hiroko Nishida, MDPhD, Mutsumi Hayashi, MD, PhD, Chikao Morimoto, MD, PhD, Michiie Sakamoto, MD, PhD, Taketo Yamada, MD,PhD

Blood (2017) 130 (Supplement 1): 4424.

https://doi.org/10.1182/blood.V130.Suppl_1.4424.4424

Published: 2017

Journal Articles

CD26 Is a Novel Target for the Treatment of Tumor Progression and Its Related Osteolytic Bone Disease in Multiple Myeloma

Hiroko Nishida, MD, PhD, Hiroko Madokoro, Hiroshi Suzuki, Mutsumi Hayashi, MD, PhD, Chikao Morimoto, MD, PhD, Michiie Sakamoto, MD, PhD, Taketo Yamada, MD, PhD

Blood (2015) 126 (23): 1809.

https://doi.org/10.1182/blood.V126.23.1809.1809

Published: 2015

Journal Articles

Humanized Anti-CD26 Monoclonal Antibody Inhibits Osteoclast Bone Resorption Activity Via Blockade Of P38MAPK Signaling In Multiple Myeloma

Hiroko Nishida, M.D., Ph.D., Hiroko Madokoro, Hiroshi Suzuki, Michiie Sakamoto, M.D., Ph.D., Chikao Morimoto, M.D., Ph.D., Taketo Yamada, M.D., Ph.D

Blood (2013) 122 (21): 1918.

https://doi.org/10.1182/blood.V122.21.1918.1918

Published: 2013

Journal Articles

TC11, a Novel Phthalimide Derivative, Directly Binds to NPM1 and Induced Apoptosis of High-Risk Myeloma Cells Via Centrosomal Disruption

Saito Sosei, Kana Yoshikawa, Noriko Tabata, PhD, Hiroshi Yanagawa, PhD, Tsukasa Oikawa, PhD, Wenlin Du, MD, PhD, Taketo Yamada, MD, PhD, Maiko Matsushita, MD, PhD, Junya Seki, Kaoru Tohyama, MD, PhD, Yutaka Hattori, MD, PhD

Blood (2012) 120 (21): 1841.

https://doi.org/10.1182/blood.V120.21.1841.1841

Published: 2012

Journal Articles

Targeting CD26 with Humanized Monoclonal Antibody, As a Novel Approach to Inhibit Human Osteoclast Differentiation and Subsequent Bone Resorption

Hiroko Nishida, MD., PhD., Hiroko Madokoro, Hiroshi Suzuki, Michiie Sakamoto, M.D., Ph.D., Chikao Morimoto, M.D., Ph.D., Taketo Yamada, MD, PhD

Blood (2012) 120 (21): 1348.

https://doi.org/10.1182/blood.V120.21.1348.1348

Published: 2012

Journal Articles

Effects of a Histone Deacetylase Inhibitor On Myeloid Leukemia Cell Line with Mixed-Lineage Leukemia Partial Tandem Duplication

Dai Keino, MD, Mutsumi Hayashi, MD, Ryo Ohyama, MD, Mizuho Morimoto, MD, Kensuke Kondoh, MD, Akira Shimada, MD, PhD, Taketo Yamada, MD, PhD, Akitoshi Kinoshita, MD

Blood (2012) 120 (21): 4331.

https://doi.org/10.1182/blood.V120.21.4331.4331

Published: 2012

Journal Articles

CD26 Blockade by Humanized Monoclonal Antibody Leads to Prophylaxis and Treatment of Graft-Versus-Host Disease (GVHD) in Hu-PBL-NOG Model Mice,

Ryo Hatano, Kei Ohnuma, Taketo Yamada, MD, PhD, Takaaki Ooki, Junpei Yamamoto, Kaoru Komoriya, Yukiko Iwata, Nam H. Dang, Chikao Morimoto

Blood (2011) 118 (21): 4018.

https://doi.org/10.1182/blood.V118.21.4018.4018

Published: 2011

Journal Articles

A Novel Anilinoquinazoline Derivative Inhibits Growth of High-Risk Myeloma Cells In Vivo and Regulates Differentiation of Osteoclasts

Yoshie Ozaki, Yuhei Naito, Hiroshi Yanagawa, PhD, Yuya Suzuki, Wenlin Du, MD, PhD, Taketo Yamada, MD, PhD, Koichi Matsuo, MD, PhD, Nobuhide Doi, PhD, Shiro Iijima, PhD, Maiko Matsushita, MD, PhD, Kayoko Tahara, PhD, Yutaka Hattori, MD, PhD

Blood (2010) 116 (21): 4076.

https://doi.org/10.1182/blood.V116.21.4076.4076

Published: 2010

Journal Articles

A Novel Function of CD26-Mediated Costimulation in the Cytotoxic Activity of Human CD8+ T Cells in Xenogeneic Chronic Graft-Versus-Host Disease (cGVHD) and GVL Mice Model.

Ryo Hatano, Kei Ohnuma, Taketo Yamada, Wataru Takasawa, Yuko Endo, Yumiko Matsumura, Osamu Hosono, Nam H. Dang, Chikao Morimoto

Blood (2009) 114 (22): 3548.

https://doi.org/10.1182/blood.V114.22.3548.3548

Published: 2009

Journal Articles

Hepatocyte Growth Factor-Producing Multiple Myeloma (HGF myeloma) Is a Distinct Clinical Entity and Needs for Molecular Targeted Therapy.

Yutaka Hattori, Shin-ichiro Okamoto, MD, PhD, Wenlin Du, Taketo Yamada, Naoki Shimada, Kunio Matsumoto, Morihiko Sagawa, Yasuo Ikeda

Blood (2008) 112 (11): 1717.

https://doi.org/10.1182/blood.V112.11.1717.1717

Published: 2008

Journal Articles

NK4, an antagonist of hepatocyte growth factor (HGF), inhibits growth of multiple myeloma cells: molecular targeting of angiogenic growth factor

Wenlin Du, Yutaka Hattori, Taketo Yamada, Kunio Matsumoto, Toshikazu Nakamura, Morihiko Sagawa, Takemi Otsuki, Takako Niikura, Toshihiro Nukiwa, Yasuo Ikeda

Blood (2006) 109 (7): 3042–3049.

https://doi.org/10.1182/blood-2006-02-003103

Published: 2006

Journal Articles

5HPP-33, a Novel Tubulin-Polymerization Inhibitor Derived from Thalidomide, Directly Inhibits Proliferation and Induces Apoptosis of Human Multiple Myeloma Cells.

Toyotaka Iguchi, MD, Sawako Oda-Nakazato, MD, Tomomi Noguchi, MS, Yuichi Hashimoto, PhD, Yutaka Hattori, MD, Taketo Yamada, MD, Yasuo Ikeda, MD, Masahiro Kizaki, MD

Blood (2005) 106 (11): 1586.

https://doi.org/10.1182/blood.V106.11.1586.1586

Published: 2005

Journal Articles

NK4, an Antagonist of Hepatocyte Growth Factor (HGF), Inhibits Growth of Multiple Myeloma Cells In Vitro and In Vivo : A Mouse Model for Molecular Targeting of Angiogenic Growth Factor.

Yutaka Hattori, MD, Wenlin Du, PhD, Taketo Yamada, MD, Kunio Matsumoto, PhD, Toshikazu Nakamura, MD, Takemi Otsuki, MD, Takako Niikura, PhD, Toshihiro Nukiwa, MD, Yasuo Ikeda, MD

Blood (2004) 104 (11): 637.

https://doi.org/10.1182/blood.V104.11.637.637

Published: 2004

Journal Articles

1′-Acetoxychavicol Acetate (ACA) Is a Novel NF-κB Inhibitor with Significant Activity Against Multiple Myeloma in Vitro and in Vivo .

Keisuke Ito, MD, Tomonori Nakazato, MD, Yoshitaka Miyakawa, MD, Ming Ji Xian, MD, Taketo Yamada, MD, Hajime Ohigashi, PhD, Yasuo Ikeda, MD, Masahiro Kizaki, MD

Blood (2004) 104 (11): 765.

https://doi.org/10.1182/blood.V104.11.765.765

Published: 2004

Journal Articles

Host F1 Mice Pretreated With Granulocyte Colony-Stimulating Factor Accept Parental Bone Marrow Grafts in Hybrid Resistance System

Koho Iizuka, Hideo Kaneko, Taketo Yamada, Hiromitsu Kimura, Yasuo Kokai, Junichiro Fujimoto

Blood (1997) 89 (4): 1446–1451.

https://doi.org/10.1182/blood.V89.4.1446

Published: 1997

NARROW

Humanized Anti-CD26 Monoclonal Antibody Has Anti-Myeloma Efficacy for the Treatment of High-Risk Multiple Myeloma

CD26 Is a Novel Target for the Treatment of Tumor Progression and Its Related Osteolytic Bone Disease in Multiple Myeloma

Humanized Anti-CD26 Monoclonal Antibody Inhibits Osteoclast Bone Resorption Activity Via Blockade Of P38MAPK Signaling In Multiple Myeloma

TC11, a Novel Phthalimide Derivative, Directly Binds to NPM1 and Induced Apoptosis of High-Risk Myeloma Cells Via Centrosomal Disruption

Targeting CD26 with Humanized Monoclonal Antibody, As a Novel Approach to Inhibit Human Osteoclast Differentiation and Subsequent Bone Resorption

Effects of a Histone Deacetylase Inhibitor On Myeloid Leukemia Cell Line with Mixed-Lineage Leukemia Partial Tandem Duplication

CD26 Blockade by Humanized Monoclonal Antibody Leads to Prophylaxis and Treatment of Graft-Versus-Host Disease (GVHD) in Hu-PBL-NOG Model Mice,

A Novel Anilinoquinazoline Derivative Inhibits Growth of High-Risk Myeloma Cells In Vivo and Regulates Differentiation of Osteoclasts

A Novel Function of CD26-Mediated Costimulation in the Cytotoxic Activity of Human CD8+ T Cells in Xenogeneic Chronic Graft-Versus-Host Disease (cGVHD) and GVL Mice Model.

Hepatocyte Growth Factor-Producing Multiple Myeloma (HGF myeloma) Is a Distinct Clinical Entity and Needs for Molecular Targeted Therapy.

NK4, an antagonist of hepatocyte growth factor (HGF), inhibits growth of multiple myeloma cells: molecular targeting of angiogenic growth factor

5HPP-33, a Novel Tubulin-Polymerization Inhibitor Derived from Thalidomide, Directly Inhibits Proliferation and Induces Apoptosis of Human Multiple Myeloma Cells.

NK4, an Antagonist of Hepatocyte Growth Factor (HGF), Inhibits Growth of Multiple Myeloma Cells In Vitro and In Vivo : A Mouse Model for Molecular Targeting of Angiogenic Growth Factor.

1′-Acetoxychavicol Acetate (ACA) Is a Novel NF-κB Inhibitor with Significant Activity Against Multiple Myeloma in Vitro and in Vivo .

Host F1 Mice Pretreated With Granulocyte Colony-Stimulating Factor Accept Parental Bone Marrow Grafts in Hybrid Resistance System

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only